SCHEMBL1994150

SCHEMBL1994150

COC(=O)CN(Cc1ccc(-c2ccccc2CN2CCOCC2)cc1)C(N)=O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.43
PDE10A Q9Y233 2/20 0.42
MLNR O43193 4/20 0.42
BCL2 P10415 1/20 0.40
BCL2L1 Q07817 1/20 0.40
MAPK1 P28482 1/20 0.40
CHUK O15111 1/20 0.40
INSR P06213 1/20 0.40
MAPK8 P45983 1/20 0.40
CAMKK2 Q96RR4 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MCHR1 Q99705 2/20 0.39
HRH3 Q9Y5N1 2/20 0.39
CYP2A13 Q16696 1/20 0.39
BDKRB1 P46663 1/20 0.39
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13294069 0.72 PDE10A (0.42) DHODHPDE10ABCL2BCL2L1ALDH1A1
SCHEMBL28792722 0.72 HTR7 (0.64) HRH3CYP2A13
SCHEMBL840197 0.70 PARP1 (0.41) HRH3
SCHEMBL2627962 0.70 CYP2A13 (0.55) PDE10AALDH1A1HRH3CYP2A13HCRTR1
SCHEMBL29415418 0.69 HTR7 (0.69) DHODHPDE10AALDH1A1CYP2A13
SCHEMBL28195866 0.69 HTR7 (0.69) DHODHPDE10AALDH1A1CYP2A13
SCHEMBL2005490 0.69 CYP3A4 (0.47) DHODHALDH1A1HCRTR1HCRTR2
SCHEMBL8744977 0.69 KDM4E (0.57) MLNRBCL2BCL2L1ALDH1A1
SCHEMBL3986555 0.69 ALDH1A1 (0.52) DHODHPDE10ABCL2BCL2L1CHUK
SCHEMBL23644502 0.68 DHODH (0.51) DHODHPDE10ABCL2BCL2L1CHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 DHODH 1578/4885PDE10A 4545/4885MLNR 1516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.